Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects

2023-507997-41-00 Protocol CLI-06795AA1-09 Human pharmacology (Phase I) - Other Ended

Start 25 Jan 2024 · End 21 May 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CLI-06795AA1-09

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 1

Chronic cough

Key facts

Sponsor
Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
25 Jan 2024 → 21 May 2024
Decision date (initial)
2024-01-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic cough

VersionLevelCodeTermSystem organ class
21.1 LLT 10066656 Chronic cough 10038738

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Chiesi Farmaceutici S.p.A.

Sponsor organisation
Chiesi Farmaceutici S.p.A.
Address
Via Palermo 26 A
City
Parma
Postcode
43122
Country
Italy

Scientific contact point

Organisation
Chiesi Farmaceutici S.p.A.
Contact name
GLOBAL CLINICAL DEVELOPMENT

Public contact point

Organisation
Chiesi Farmaceutici S.p.A.
Contact name
GLOBAL CLINICAL DEVELOPMENT

Chiesi Farmaceutici S.p.A.

Sponsor organisation
Chiesi Farmaceutici S.p.A.
Address
Via Palermo 26 A
City
Parma
Postcode
43122
Country
Italy

Scientific contact point

Organisation
Chiesi Farmaceutici S.p.A.
Contact name
GLOBAL CLINICAL DEVELOPMENT

Public contact point

Organisation
Chiesi Farmaceutici S.p.A.
Contact name
GLOBAL CLINICAL DEVELOPMENT

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 24 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
SGS Belgium
SGS-Clinical Research CPU, Drie Eikenstraat 655, 2650, Edegem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-01-25 2024-05-21 2024-02-19 2024-04-08

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-28 Belgium Acceptable
2024-01-15
2024-01-22
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-04-09 Belgium Acceptable
2024-01-15
2024-04-09